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Introduction
The skeletal system is composed of a variety of special-
ized forms of supporting or connective tissue, and bone pro-
vides a rigid protective and supportive framework for most 
of the soft tissues of the body1. Naturally, bone also acts as 
a calcium reservoir and is important in calcium homeosta-
sis; additionally, bone is a metabolically active tissue, and 
its formation, modeling and remodeling are influenced by 
many factors or conditions, especially hormonal and dietary 
factors or conditions1,2. The above facts mean that the skele-
tal system has one of the most important functions of all the 
organs, and it is important to identify changes in the skeletal 
system in toxicological studies. On the other hand, a large 
number of bones have multiple functions in animal bodies 
and differ from one another to some degree in terms of de-
velopment and growth. For instance, the fetal development 
of bone occurs in two ways, intramembranous ossification 
and endochondral ossification1. In addition, the time of fu-
sion of the secondary ossification centers in the long bones 
is known to vary in men, rats and other animals3, and the 
maturation process differs in various bones at the same age.
The pathologic and physiologic mechanisms of toxic 
bone disease are often not well understood4. The number 
of agents reported to have a direct toxic effect on bone or 
cartilage has been somewhat limited, and we may have not 
yet learned how to evaluate the early primary toxic effects 
of drugs, chemicals or other environmental agents on hard 
tissues4. Some agents that cause skeletal pathologic changes 
are known, such as corticosteroids, causing aseptic necrosis 
of the femoral head4,5, and bisphosphonate, causing inhibi-
tion of osteoclast function4,6. Doxorubicin (DOX), a cancer 
chemotherapeutic  agent,  is  well  known  to  induce  major 
toxicities such as cardiotoxicity7,8 and glomerulonephropa-
thy7,9, in addition to inhibiting the proliferation of growth 
plate chondrocytes, leading to growth plate thinning and 
longitudinal growth retardation when weanling rats (around 
4 weeks old) are treated with DOX10.
However,  most  exogenous  chemicals  are  known  to 
exert their effects on the skeleton via secondary mecha-
nisms, usually mediated by alterations in blood flow within 
the skeleton, and substances inducing secondary skeletal 
changes are usually either hormones, vitamins or minerals 
or affect the metabolism of skeletal-regulating agents4. Age 
is also known to affect the responsiveness of the skeletal 
system, and it is well recognized that fracture healing is less 
vigorous in older individuals than in young individuals4. 
Consequently, age-related changes and treatment-induced 
changes are not uniform throughout the skeleton11.
Evaluating bone toxicity can be problematic for sev-
eral reasons. One issue is the age of the animals at the time 
of evaluation. Practically, the femur and sternum are often 
included in standard tissue lists of bone toxicity when bone 
is evaluated in repeat-dose toxicity studies morphological-
ly12–15, and these bones are typically used in animals of all 
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ages and in both short-term and long-term studies, though 
the time of epiphyseal closure is known to differ in some 
regions3,16. For instance, in the distal femur, proximal hu-
merus and tibia, the time of fusion of the secondary ossifi-
cation centers varies, as shown using X-ray radiography in 
rats around 50 weeks of age3. In this situation, whether the 
evaluation of bone toxicity can be effectively performed in a 
practical manner remains debatable.
Bone toxicity must be measured accurately using ani-
mals of an appropriate age; for this purpose, the bone regions 
most suitable for evaluating bone toxicity must be deter-
mined according to the age of the animal model. Therefore, 
the present study was performed to investigate histopatho-
logically possible differences in the effects on bones in dif-
ferent regions and with different time of epiphyseal closure 
in aged rats (around 50 weeks old) dosed with DOX.
Materials and Methods
Experimental animals
Eight  46-week-old  male  Crl:CD  (SD)  rats  weigh-
ing 649–910 g and four 8-week-old male Crl:CD (SD) rats 
weighing 293–333 g purchased from Charles River Japan 
(Kanagawa, Japan) were maintained under the following 
conditions: temperature of 20–26 °C, relative humidity of 
30–70%, a 12-h light/dark cycle and a ventilation frequency 
of 5–40 air exchanges/h. Each rat had free access to a labo-
ratory pellet diet for rats (MF, Oriental Yeast Co., Ltd., To-
kyo, Japan) and tap water. The maintenance and experimen-
tal protocols conformed to the Guide for the Care and Use 
of Laboratory Animals of Taisho Pharmaceutical Co., Ltd.
Study design
Eight rats at 46 weeks of age were divided into two 
groups of four: a control group and a DOX-treated group. 
DOX (Doxorubicin; Kyowa Hakko Kogyo, Tokyo, Japan) 
was administered 5 times every second week by injection 
into the tail vein at doses of 15 and 0 (control) mg/m2 body 
surface area; the former dose is known to affect the growth 
plate of rats at an age of 4–5 weeks10. The body surface area 
(BSA [m2]) was calculated for each rat using the following 
formula: BSA = k•w2/3/104, with k = constant [m2/gr2/3 ], 
chosen to be 9·5, and w = weight [grams]. The animals were 
euthanized at 55 weeks of age at the end of the study period 
one week after the last administration of DOX, except for 
one of the DOX-treated animals that died at 53 weeks of age 
because of exhaustion and wasting. To compare the bones of 
aged rats with young rats and detect of cellular proliferation, 
four rats at 8 weeks of age that were not treated with DOX 
were euthanized and used as positive control specimens.
Histopathologic methods
The growth plates, articular cartilage and cortical bone 
of the distal femur, sternum (4th sternebra), proximal hu-
merus and tibia were histopathologically examined in all 
the animals. Samples were fixed with 10% neutral buffered 
formalin, decalcified with Plank-Rychlo’s solution, embed-
ded in paraffin and sectioned at a thickness of 4–5 mm. The 
specimens were stained with hematoxylin and eosin (HE) 
and were histologically examined using a light microscope 
similar  to  the  routine  histopathological  evaluations  per-
formed in toxicity studies. For qualitative analysis of cel-
lular proliferation, the specimens of all regions were as-
sessed by immunohistochemical staining for proliferating 
cell nuclear antigen17 ([PCNA], PC10, Dako, Japan) using 
the LSAB method (Dako LSAB2 kit; Dako, Japan) and the 
same regional specimens in young rats (8 weeks old) as a 
positive control for PCNA, as mentioned above.
Histomorphometric methods
HE stained sections were viewed under a light micro-
scope at a magnification of ×40, and measurements were 
performed  using  the  image  analysis  software  Image-pro 
PLUS (Verion 6.3, Media Cybernetics, Nippon Roper Co., 
Ltd.). To measure the growth plate height, three areas per 
section were analyzed. Standard histomorphometry nomen-
clature, symbols and calculations were used18. Ten areas per 
section were analyzed for osteoblast and osteoclast num-
ber per bone perimeter (Ob.N/B.Pm; Oc.N/B.Pm). Though 
an exact discrimination of these cells is difficult using HE 
staining, these cells were distinguished as follows. Osteo-
clasts  were  regarded  as  large  multinucleated,  resorbing 
cells, whereas osteoblasts were regarded as mononuclear 
and cuboidal or columnar bone lining cells with abundant 
basophilic cytoplasm1,2,18.
Statistical analyses
The mean value and standard error (S.E.) of the nu-
merical data obtained from the histomorphometric analysis 
were calculated for each group. To analyze the differences 
in several regions of bone in the control group, the statistical 
significance between the femur, which is often included in 
standard tissue lists for bone toxicity, and each other bone 
(sternum,  tibia,  humerus)  was  analyzed  using  a  multiple 
comparison test. For comparison of 3 or more bones, the ho-
mogeneity of variance was analyzed using the Bartlett test 
(p < 0.05) followed by a one-way analysis of variance when 
the variance was homogeneous. If a significant difference 
was found among the groups, the Dunnett test (paramet-
ric) was performed to test the differences between the mean 
values for the femur and each of the other bones. When the 
variance was heterogeneous, the Kruskal-Wallis H-test (p 
< 0.05) was applied; if a significant difference was found 
among the groups, the Dunnett test (nonparametric) was 
performed to test the differences between the mean values 
for the femur and each of the other bones. To analyze the 
bones between the control and DOX-treated animals, the 
statistical significance of differences between the control 
and DOX-treated group was analyzed for equality of vari-
ance using the F-test (p < 0.05), and then the Student’s t-test 
or Aspin-Welch t-test was conducted depending on whether 
the variances were equal or not. The SAS preclinical pack-
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age (version 5.0, SAS Institute Inc.) was used for the statisti-
cal analyses.
Results
Growth plate morphology of aged rats in the control 
group
In the control rats, the histomorphological results for 
the growth plates were quite distinct for each region. Re-
garding the heights of the growth plate in the HE stained 
section, the proximal humerus and tibia were thicker and 
arranged in regularly characteristic longitudinal columns 
compared with the distal femur and sternum (Fig 1). When 
compared with the femur, a standard tissue commonly used 
in toxicological studies, and other bones using a histomor-
phometric analysis, no significant changes were observed, 
although the growth plate height tended to be thicker in the 
tibia and humerus (Fig 2). According to Ob.N/B.Pm and 
Oc.N/B.Pm, the Oc.N/B.Pm of the tibia was significantly 
larger than that in the femur and other bones in the control 
group (Figs 3 and 4). To determine the incidence of chon-
drocyte proliferation, sections were stained for PCNA, a 
marker for proliferating cells17; the heights of the growth 
plate differed widely among the regions, but PCNA-positive 
cells were not obvious in all regions. In a young animal as a 
positive control for PCNA, the growth plates had plenty of 
height, and a high incidence of chondrocytes in the prolif-
erative zone was observed in all the regions (Fig 5).
Growth plate morphology of the tibia and humerus in 
DOX-treated rats
DOX-treated  rats  exhibited  some  histopathological 
changes compared with the control group; however, these 
changes differed in each region. In the proximal tibia, a re-
markable thinning of the growth plate was observed in the 
majority of DOX-treated animals; in particular, the zone 
of hypertrophy and calcification and the zone of cartilage 
degeneration decreased or disappeared in the humerus and 
tibia in the DOX-treated group, and the growth plate of the 
DOX-treated animals was thinner than that in the control 
(Fig 5). These histomorphometric changes were significant 
(Fig 2). No significant changes in Ob.N/B.Pm and Oc.N/B.
Pm were observed (Figs 3 and 4). PCNA-positive cells were 
not obvious in all regions (Fig 5). In the proximal humerus, 
the results were the same as those for the proximal tibia; 
however, in the proximal tibia, the growth plate height was 
significantly thicker than that in the proximal humerus.
Growth plate morphology of the femur and sternum in 
DOX-treated rats
In the distal femur and sternum, thinning of the growth 
plate was not remarkably observed.
In the femur and sternum, a few chondrocytes were 
present in the growth plate, and the heights of the growth 
plates were similar to those in the DOX-treated group (Fig 
1). The zone of hypertrophy and calcification and the zone of 
cartilage degeneration almost disappeared in both the femur 
and the sternum, and remarkable thinning of the growth 
plate was not observed. In addition, the osteogenic zone was 
relatively thick in the sternum in both groups and not ar-
ranged in characteristic longitudinal columns composed of 
small chondrocytes compared with the other bones. No sig-
nificant changes in the histomorphometrical analysis were 
observed (Fig 2). In the femur, the zone of cartilage degen-
eration of the metaphysis tended to disappear but partially 
remained. Regarding the Ob.N/B.Pm and Oc.N/B.Pm, no 
significant changes were observed, but higher values tended 
to be observed in the DOX-treated group (Fig 3 and 4).
Concerning articular cartilage, cortical bone and the 
cellular morphology of osteoclasts and osteoblasts, no re-
markable findings were observed in any of the regions. In 
the growth plates of the aged control and DOX-treated ani-
mals, the height of the growth plate differed widely among 
the  regions,  as  mentioned  above,  though  PCNA-positive 
cells were not obvious in all the regions.
Discussion
Practically, when bone is evaluated morphologically in 
repeat-dose toxicity studies in rats, the femur and sternum 
are often included in standard tissue lists for the evaluation 
of bone toxicity, as recommended in the guidelines of the 
Pharmaceuticals and Medical Devices Agency (PMDA) and 
the Food and Drug Administration (FDA)12–15. These meth-
ods are suitable for evaluation of bones in growing animals 
in toxicological studies. However, drug safety must also be 
evaluated in toxicity studies at other growth stages, such as 
in weanling animals for evaluation of infant, and aged ani-
mals for evaluation of aging people. Thus, it is important to 
evaluate drug safety in consideration of the action and indi-
cations of the drugs. The aim of this study was to examine 
the evaluation of bone toxicity in consideration of the age of 
the animals.
First of all, the morphological differences of the aged 
rats in the control group were examined. In the control aged 
rats, the histomorphological results for growth plates were 
quite distinct in each region. Regarding the height of the 
growth plate in HE-stained sections, the growth plates of 
the proximal humerus and tibia were thicker and arranged 
regularly in characteristic longitudinal columns compared 
with the distal femur and sternum. In comparison with the 
femur, a standard tissue commonly used in histomorphomet-
ric analyses for toxicological studies, no significant changes 
were observed, although the growth plate height tended to 
be thicker in the tibia and humerus. Moreover, the Oc.N/B.
Pm in the tibia was increased significantly compared with 
that in the femur in the control group.
On the other hand, a large number of bones have mul-
tiple functions in animal bodies and differ from one another 
to some degree in terms of development and growth. For 
instance, fetal development of bone occurs in two ways1. 
The bones of the vault of the skull, the maxilla and most 
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Fig. 1.  Histopathological changes of the growth plate in aged rats. The growth plates (GP) of the (a) humerus, (b) femur and (c) sternum are 
shown for the control group. The GP of the (d) humerus, (e) femur and (f) sternum are shown for the DOX-treated group. (a–c) The GP 
in the humerus is thicker than those of the femur and sternum in the control. (d) In comparison of the humerus between the control and 
DOX-treated animals, the GP in the DOX-treated group was obviously thinner than that in the control. In addition, the zone of hyper-
trophy and calcification and the zone of cartilage degeneration decreased or disappeared. (e) Remarkable thinning of the GP was not 
observed in the femur of the DOX-treated group, and the zone of hypertrophy and calcification and the zone of cartilage degeneration 
almost disappeared in both groups, though the zone of cartilage degeneration partially remained in the femur. (f) The thinning of the 
GP was not remarkably observed in the sternum of the DOX-treated group, and the zone of hypertrophy and calcification and the zone 
of cartilage degeneration practically disappeared in both groups. Moreover, the osteogenic zone was thick in both groups. HE staining. 
Scale bars indicate 100 mm.45   Noguchi, Miyata, Sato et al.
of the mandible are formed by direct replacement of mes-
enchyme with bone1. This process is called intramembra-
nous ossification and results in so-called membrane bones1. 
In contrast, the long bones, vertebrae, pelvis and bones of 
the skull are preceded by the formation of a continuously 
growing cartilage model that is progressively replaced by 
bone1. This process is called endochondral ossification and 
enables the formation of bone that is capable of sustaining 
functional stresses, resulting in the formation of so-called 
cartilage bones1. During endochondral ossification, replace-
ment with bone begins at the primary ossification center in 
the diaphysis, with regressive changes and bone formation 
also occurring from a secondary ossification center in the 
epiphyses1. At physical maturity, the process of endochon-
dral ossification ceases, and fusion of the secondary ossifi-
cation centers occurs1. In addition, the time of fusion of the 
secondary ossification centers in the long bones is known 
to vary in men, rats and other animals3, and the maturation 
process differs in various bones at the same age. In other 
words, the maturation processes of the respective second-
ary ossification centers vary with the bones, which might 
be classified into the following three types: (1) acute ossi-
fication type, which requires a relatively short period from 
the time of appearance until fusion; (2) delayed ossification 
type, which requires a relatively long period for completion 
of fusion; and (3) incomplete ossification type3. In the pres-
ent study, the distal femur appeared to be an acute ossifica-
tion type, the proximal humerus appeared to be a delayed 
ossification type and the proximal tibia appeared to be an 
incomplete ossification type3. In detail, the time of fusion 
of the secondary ossification centers was 15–17 weeks in 
the distal femur, 52 weeks in the proximal humerus and 104 
weeks or longer in the proximal tibia3. The incomplete os-
sification type is thought to be characteristic of certain ro-
dents such as rats and mice, and the time of 17 to 21 weeks 
would be considered the endpoint of the maturation process 
in the rat3. However, extensive remodeling and bone forma-
Fig. 2.  Growth plate heights of the distal femur, sternum, proximal 
tibia and humerus after treatment with DOX in aged rats. The 
growth plates of the tibia and humerus in the DOX-treated 
group  became  significantly  thinner  than  those  in  the  con-
trol group. Values are means ± SEM (n=3–4 animals/group).   
* p<0.05 for comparisons of the humerus between the DOX-
treated group and control group. ** p<0.01 for the compari-
sons of the tibia between the DOX treated group and control 
group.
Fig. 3.  Ob.N/B.Pm of the distal femur, sternum, proximal tibia and 
humerus after treatment with DOX in aged rats. The Ob.N/B.
Pm of the femur and sternum in the DOX-treated group tend-
ed to be higher than those in the control group. Values are 
means ± SEM (n=3–4 animals/group).
Fig. 4.  Oc.N/B.Pm of the distal femur, sternum, proximal tibia and 
humerus after treatment with DOX in aged rats. The Oc.N/B.
Pm of the tibia in the control group was significantly higher 
than that of the femur in the control group. Values are means 
± SEM (n=3–4 animals/group). # p<0.05 for comparisons be-
tween the femur and tibia in the control group.46 Bone Toxicity in Aged Rats
Fig. 5.  Changes of histopathological and immunohistochemical staining in chondrocytes of the proliferative zone in the growth 
plate of the tibia. (a) The growth plates (GP) of the young control animals were positive for PCNA expression in the nuclei 
of the chondrocytes. (b) The GP of the aged control animals showed no obvious staining for PCNA. (c) The GP of the aged 
DOX-treated animals showed no obvious staining for PCNA. (d) The growth plates of the young animals were relatively 
thick (HE staining). (e) The GP of the aged control animals were thinner than those of the young animals, particularly in 
the zone of hypertrophy and calcification and the zone of cartilage degeneration (HE staining). (f) The GP of the DOX-
treated animals were much thinner than those of the aged control animals, and in approximately half of the animals, the 
zone of hypertrophy and calcification and the zone of cartilage degeneration had decreased or disappeared (HE staining). 
Scale bars indicate 100 mm.47   Noguchi, Miyata, Sato et al.
tion occur within cellular regions of the growth plate, and 
direct bone formation by former growth plate chondrocytes 
are in progress during this period17. These changes were 
reflected in the aged control rats in that the heights of the 
growth plates in the proximal humerus and tibia were thick-
er and arranged regularly in characteristic longitudinal col-
umns compared with those in the distal femur and sternum. 
Particularly, a significantly large Oc.N/B.Pm was observed 
in the tibia; consequently, the proximal tibia was thought to 
be an incomplete ossification type. These data suggest that 
the growth plate of the tibia would reflect only slight effects 
in toxicology studies performed in aged rats. Concerning 
the sternum, the time of fusion of the secondary ossification 
centers has not been previously reported, although thicken-
ing of the trabecular bone has been observed in rats at 180 
days old19, and the cartilage cells in the proliferating zone 
were confined to fewer layers than in the sternum of 8 week-
old rats. Similar results were also observed in the present 
study.
When the control and DOX-treated groups were com-
pared,  pathological  changes  in  the  heart,  appearing  as 
vacuolization of the myocytes8, and kidney, appearing as 
vacuolization of the glomerular basement membrane9, were 
confirmed, indicating that DOX was administered at a toxic 
dose (data not shown). Nevertheless, observation of the fe-
mur and sternum, two standard tissues often used in toxicol-
ogy studies, did not show obvious toxic effects of DOX.
It is also well known that thinning of the growth plate 
is observed in growing animals dosed with DOX, such as 
weanling rats10 and young rabbits (around 6–8 weeks old)20. 
In the present study, thinning of the growth plate was also 
observed in aged rats, not in the distal femur and sternum, 
but in the proximal humerus and tibia. In this study, the 
rats were treated from 46 weeks of age, which is when the 
proximal humerus (a delayed ossification type bone) had not 
yet undergone fusion of the secondary ossification centers 
or epiphyseal union; thinning of the growth plate was ob-
served in these bones, which is similar to the observations 
in growing animals. This phenomenon was also observed 
in the proximal tibia, an incomplete ossification-type bone. 
As for the distal femur, the time of fusion of the second-
ary ossification centers (epiphyseal union) had already oc-
curred, and the growth plate had become thinner than those 
of the proximal humerus and tibia, so no obvious thinning 
of the growth plate was observed. In the control animals 
in this study, the growth plate of the sternum was thinner 
than those of the proximal humerus and tibia but similar to 
that of distal femur, which is an acute ossification type bone; 
consequently, no obvious thinning of the growth plate was 
observed in the DOX-treated rats.
DOX is known to inhibit the proliferation of growth 
plate  chondrocytes10.  In  addition,  the  mechanism  of  this 
change has been considered to be as follows. DOX is a well-
known anthracycline and DNA intercalator, which is the 
main factor of epiphyseal growth21, and the inhibitory ac-
tion of DOX on DNA-directed RNA synthesis and protein 
synthesis tends to retard the production of cartilage matrix 
in  growing  animals20.  DOX  also  reportedly  binds  to  the 
crystalline surfaces of bone in vitro; therefore, DOX affects 
adversely both the organic and inorganic fractions of bone20. 
Though PCNA-positive cells were not obvious in all the 
growth plates observed in the control and DOX-treated aged 
rats in the present study, the inhibitory action of DOX on 
DNA-directed RNA synthesis did not cause the thinning of 
the growth plate in the aged animals. It seems that the thin-
ning of the growth plate in aged animals would be caused by 
DOX binding to the crystalline surfaces of bone.
The growth plate morphology of the aged rat differs 
from that of the young rat. For instance, despite the contin-
ued presence of growth plate in the aged rat, longitudinal 
growth no longer occurs17. In the aged rat, it is similar to en-
dochondral ossification in that resorption of cartilage matrix 
is followed by bone deposition onto the walls of the resorbed 
cavities. Though the location of this ossification is different, 
it is found within the core of the growth plate cartilage in the 
aged rat, not within the vascular/marrow space as would be 
the case in a younger rat17. Moreover, in the growth plate of 
the aged rat, the proliferation of chondrocytes is inhibited, 
some chondrocytes become bone-forming cells and direct 
bone formation occurs in the former growth plate chondro-
cytes17. Considering such a particular process of the growth 
plate in the aged rat, DOX would bind to the crystalline sur-
faces of bone that formed directly in the growth plate and 
prevent direct bone formation in the growth plate and then 
cause thinning of the growth plate in aged animals.
According to the Ob.N/B.Pm and Oc.N/B.Pm, no sig-
nificant  changes  were  observed  between  the  control  and 
DOX-treated groups, though higher values tended to be ob-
served in the femur and sternum of the DOX-treated group. 
As stated above, the mechanisms of DOX affecting bone 
are the inhibitory action of DOX on DNA-directed RNA 
synthesis and binding of DOX to the crystalline surfaces of 
bone. Moreover, numerous reports have discussed how the 
number and activities of osteoclasts and osteoblasts change 
in DOX-treated animals, and the effects of osteoclasts and 
osteoblasts varied widely among the regions examined in 
the present study as well as in previous reports7,20,22. These 
reports suggest that the changes of Ob.N/B.Pm and Oc.N/B.
Pm would be indirect changes related to a primary change 
in the bone, which is thinning of the growth plate, or kidney 
failure. In this study, the increases in the Ob.N/B.Pm and 
Oc.N/B.Pm of the femur and sternum were thought to be 
secondary changes, and a direct change, caused by DOX, 
thinning of the growth plate, was observed in the tibia and 
humerus. These data suggest that the growth plates of the 
tibia and humerus are more suitable for evaluation of toxic-
ity studies in aged rats than the femur and sternum. More-
over, further study is required using chemicals that have 
other toxicological mechanisms, that affect osteoclasts, os-
teoblasts and so forth.
In conclusion, the results of the present study suggest 
that  some  differences  in  bone  regions  exist  in  aged  rats 48 Bone Toxicity in Aged Rats
treated with DOX, depending on the time of epiphyseal clo-
sure. Thus, the area of observation must be considered when 
evaluating bone toxicity in aged rats, since the bone matura-
tion process varies according to bone type in rats. In addi-
tion, this opinion should be studied further using chemicals 
that have other toxicological mechanisms.
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